Skip to main content
SpringerLink
Log in

Questions and Answers

  • Published:
Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Lichtlen PR, Hugenholtz PG, Rafflenbeul W, et al., on behalf of the INTACT group investigators. Retardation of angiographic progression of coronary artery disease by nifedipine. Lancet 1990; 335: 1109–13

    Article  PubMed  CAS  Google Scholar 

  2. Waters D, Freedman D, Lesperence J, et al. Design features of a controlled clinical trial to assess the effect of a calcium entry blocker upon the progression of coronary artery disease. Control Clin Trials 1987; 8: 216–42

    Article  PubMed  CAS  Google Scholar 

  3. Mak IT, Boehme P, Weglicki WB. Antioxidant effects of calcium channel blockers against free radical injury in endothelial cells. Circ Res 1992; 70: 1099–103

    Article  PubMed  CAS  Google Scholar 

  4. Brown MJ, Castaigne A, Ruilope LM, et al. INSIGHT: International GITS Study Intervention as a goal in hypertension treatment. J Human Hypertens 1966; 10Suppl. 3: S157–S160

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Questions and Answers. Drugs 53 (Suppl 1), 42–44 (1997). https://doi.org/10.2165/00003495-199700531-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199700531-00007

Keywords

Search

Navigation